Last reviewed · How we verify
Treatment 2 Ondansetron
Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Prevention of nausea and vomiting induced by chemotherapy, Prevention of post-operative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.
At a glance
| Generic name | Treatment 2 Ondansetron |
|---|---|
| Also known as | Zofrane |
| Sponsor | Hamad Medical Corporation |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ondansetron is a selective 5-HT3 receptor antagonist that inhibits serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. By blocking these receptors, it prevents the emetic signals that trigger nausea and vomiting, particularly those induced by chemotherapy, radiation, or post-operative conditions.
Approved indications
- Prevention of nausea and vomiting induced by chemotherapy
- Prevention of post-operative nausea and vomiting
- Prevention of radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
- Fever
Key clinical trials
- Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PHASE3)
- The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities (PHASE2)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (PHASE3)
- Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis (NA)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Ondansetron for the Management of Atrial Fibrillation (PHASE4)
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment 2 Ondansetron CI brief — competitive landscape report
- Treatment 2 Ondansetron updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI